Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
Silver
H
H
Aharon
N
N
Schwartz
M
M
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications*; D004409:Dyskinesia, Drug-Induced / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D011388:Prolactin / Q000097:blood; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy*; D018967:Risperidone / Q000009:adverse effects*
D014150:Antipsychotic Agents; D011388:Prolactin; D018967:Risperidone